Novel generations of influenza vaccines

Vaccine

Volumn 21, Issue 16, 2003, Pages 1789-1795

  Kemble, George ^a   Greenberg, Harry ^b  

^a MEDIMMUNE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Adjuvants; Immunogenicity; Influenza

Indexed keywords

ALUMINUM; CHOLESTEROL; DNA VACCINE; ESCHERICHIA COLI ENDOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; PROTEIN M2; PROTEIN NP; SAPONIN; UNCLASSIFIED DRUG; VIROSOME VACCINE; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTHRALGIA; BELL PALSY; CELL LINE; CELL STRAIN; CLINICAL TRIAL; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG QUALITY; DRUG USE; ERYTHEMA; EVALUATION; FEVER; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LICENSING; METHODOLOGY; MOLECULAR BIOLOGY; MYALGIA; NONHUMAN; NOSE MUCOSA; PAIN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INDURATION; VACCINE PRODUCTION; VERO CELL; VIRUS CULTURE; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 0037403081     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00074-4     Document Type: Review

References (59)

1. Simonsen L.et al. The impact of influenza epidemics on hospitalizations. J. Infect. Dis. 181(3):2000;831-837.
2. Thompson W.W.et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289(2):2003;179-186.
3. Bridges C.B.et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 51(RR-3):2002;1-31.
4. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Malden: Blackwell Scientific Publication; 1998. p. 3-18.
5. Glezen W.P. Emerging infections: pandemic influenza. Epidemiol. Rev. 18(1):1996;64-76.
6. Wright PF, Webster Robert G. Orthomyxoviruses. In: Knipe D, Howley P, editors. Fields virology. 4th ed. Lippincott: Williams & Wilkins; 2002.
7. Patriarca P.A., Weber J.A., Parker R.A.et al. Efficacy of influenza vaccine in nursing homes. JAMA. 253(8):1985;1136-1139.
8. Gross P.A.et al. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J. Infect. Dis. 136(5):1977;623-632.
9. Wright P.F.et al. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J. Infect. Dis. 136(Suppl):1977;S731-S741.
10. Hehme N.et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol. 191:2002;203-208.
11. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 19(17-19):2001;2673-2680.
12. Nicholson K.G.et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 357(9272):2001;1937-1943.
13. Rimmelzwaan G.F.et al. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine. 20(1-2):2001;158-163.
14. Rimmelzwaan G.F.et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J. Gen. Virol. 78(Part 4):1997;757-765.
15. Rimmelzwaan G.F.et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine. 19(9-10):2000;1180-1187.
16. Provinciali M.et al. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech. Ageing Dev. 77(2):1994;75-82.
17. Ramanathan R.K.et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J. Clin. Oncol. 20(21):2002;4313-4318.
18. Babai I.et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 20(3-4):2001;505-515.
19. Chen D.et al. Adjuvantation of epidermal powder immunization. Vaccine. 19(20-22):2001;2908-2917.
20. Waldman R.H.et al. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull World Health Organ. 41(3):1969;543-548.
21. Greenbaum E.et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine. 20(78):2002;1232-1239.
22. Greenbaum E.et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J. Med. Virol. 65(1):2001;178-184.
23. Kiderman A.et al. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98. J. Clin. Virol. 20(3):2001;155-161.
24. Boyce T.G.et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine. 19(23):2000;217-226.
25. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine. 20(Suppl 1):2001;S42-S44.
26. Plante M.et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine. 20(1-2):2001;218-225.
27. Palese P., Garcia-Sastre A. Influenza vaccines: present and future. J. Clin. Invest. 110(1):2002;9-13.
28. Ulmer J.B. Influenza DNA vaccines. Vaccine. 20(Suppl 2):2002;S74-S76.
29. Heinen P.P.et al. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 83(Part 8):2002;1851-1859.
30. Neirynck S.et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10):1999;1157-1163.
31. Brands, et al. InfluvacTC: a safe Madin Darby canine kidney (MDCK) cell culture based influenza vaccine. Dev Biol Stand 1999;98:93-100.
32. Palache A.M.et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98:1999;115-125. discussion 133-4.
33. Halperin S.A.et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine. 20(78):2002;1240-1247.
34. Kistner O.et al. Development of a novel mammalian cell (Vero)-derived influenza vaccine. Vaccine. 16:1998;960-968.
35. Kistner O.et al. A novel mammalian cell (Vero) derived influenza virus vaccine development, characterization and industrial scale production. Wiener Klinishce Wochenschrift. 111(5):1999;207-214.
36. Bruhl P.I.et al. Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine. 19(9-10):2000;1149-1158.
37. Pau M.G.et al. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine. 19(17-19):2001;2716-2721.
38. Seo S.H.et al. Characterization of a porcine lung epithelial cell line suitable for influenza virus studies. J. Virol. 75(19):2001;9517-9525.
39. Levandowski R.A. Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines. Dev. Biol. Stand. 98:1999;171-175. discussion 197.
40. Griffiths E. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production. Dev. Biol. Stand. 98:1999;153-157. discussion 167.
41. Tree J.A.et al. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus a vaccine strains. Vaccine. 19:2001;3444-3450.
42. Govorkova E.A.et al. African Green Monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J. Virol. 70:1996;5519-5524.
43. Levandowski R.A. Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines. Dev. Biol. Stand. 98:1999;171-175.
44. Lin Y.P.et al. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology. 233:1997;402-410.
45. Kendal A.P. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries. Eur. J. Epidem. 13:1997;591-609.
46. Murphy B.R., Coelingh K. Principles underlying the development and use of live, attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 15:2002;295-323.
47. Jin H, et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology, 2003, in press.
48. Belshe R.B., Gruber W.C. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Phil. Trans. R. Soc. Lond. 356:2001;1947-1951.
49. Belshe R.B.et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine [see comments]. J. Pediatr. 136(2):2000;168-175.
50. Nichol K.L.et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial [in process citation]. JAMA. 282(2):1999;137-144.
51. Belshe R.B., Gruber W.C. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr. Infect. Dis. J. 19(Suppl 5):2000;S66-S71.
52. Update: Influenza Activity - United States, 1997-98 Season. MMWR Weekly 1998;47:196-200.
53. Influenza A - Florida and Tennessee, July-August 1998, and virologic surveillance of influenza, May-August 1998. MMWR Weekly 1998;47:756-9.
54. Neumann G.et al. Generation of influenza A viruses entirely from cloned cDNAs [see comments]. Proc. Natl. Acad. Sci. USA. 96(16):1999;9345-9350.
55. Fodor E.et al. Rescue of influenza A virus from recombinant DNA. J. Virol. 73(11):1999;9679-9682.
56. Hoffmann E. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci USA, 2002.
57. Hoffmann E.et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA. 97(11):2000;6108-6113.
58. Watanabe T.et al. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology. 299(2):2002;266-270.
59. Watanabe T.et al. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76(2):2002;767-773.